Question 1

What is Panitumumab?

Accepted Answer

Panitumumab is a type of medication known as a monoclonal antibody. It works as an epidermal growth factor receptor (EGFR) antagonist, which means it binds to specific receptors on the surface of cells.

By attaching to these receptors, the medication interferes with the signals that tell cells to grow and multiply. This action helps to slow or stop the progression of certain growths within the body.

Question 2

What is Panitumumab used for?

Accepted Answer

Panitumumab is used to treat KRAS wild-type metastatic colorectal cancer .

Question 3

How does Panitumumab work?

Accepted Answer

Targeting Cancer Cells

Panitumumab belongs to a class of medications known as monoclonal antibodies. These are laboratory-made proteins designed to recognize and attach to specific targets in the body. In the case of panitumumab, the target is the epidermal growth factor receptor (EGFR).

Blocking Growth Signals

EGFR is a protein found on the surface of both normal cells and certain types of cancer cells. When naturally occurring substances in the body bind to these receptors, they send signals that tell the cell to grow, multiply, and survive. Panitumumab works by:

Binding to the receptor: The medication attaches itself to the EGFR on the surface of the cancer cells.

Interfering with signals: By occupying the receptor, it prevents other growth-promoting proteins from attaching.

Inhibiting cell growth: Without these growth signals, the cancer cells may stop dividing and eventually die.

The Role of Genetic Markers

The effectiveness of panitumumab depends on the genetic makeup of the tumor. It is primarily used for cancers that have a "wild-type" KRAS gene. If the KRAS gene is mutated, the cancer cell may continue to grow even if the EGFR is blocked, because the mutation provides an internal signal for the cell to keep dividing regardless of external triggers.

Question 4

What are the brand names for Panitumumab?

Accepted Answer

Panitumumab is sold under the brand name Vectibix .

Question 5

What are the active ingredients in Panitumumab?

Accepted Answer

The active ingredient in Panitumumab is panitumumab .

Question 6

What are the side effects of Panitumumab?

Accepted Answer

Common side effects of Panitumumab may include:

Skin rash

Pruritus

Diarrhea

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Panitumumab?

Accepted Answer

Panitumumab belongs to the monoclonal antibody drug class.

Question 8

What is the dosage of Panitumumab and how do I take it?

Accepted Answer

Administration

Panitumumab is given as an infusion into a vein (intravenously). A healthcare provider will administer the medication in a medical setting, such as a hospital or clinic.

Frequency

The medication is generally scheduled for administration once every 14 days. The total duration of the infusion depends on the amount of medication being given.

Missed Dose

If you miss an appointment for your infusion, contact your healthcare provider as soon as possible to reschedule. It is important to stay on the prescribed schedule to ensure the medication is effective.

Preparation and Precautions

Before the infusion, the medication is prepared by a healthcare professional. It must not be shaken and is delivered through an infusion pump using a specific filter. Your doctor may also prescribe other medications to help prevent or manage side effects during the treatment process.

Question 9

Is Panitumumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Panitumumab can cause harm to a developing fetus when administered to a pregnant woman. Animal studies have shown that the medication can lead to embryo-fetal toxicity and pregnancy loss. It is important to inform a healthcare provider if you are pregnant or planning to become pregnant before starting this treatment.

Individuals who can become pregnant should use effective contraception during treatment with panitumumab and for at least 2 months after the final dose. If a patient becomes pregnant while receiving this medication, they should be informed of the potential hazards to the fetus.

Breastfeeding

It is not known whether panitumumab passes into human breast milk. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. Healthcare providers typically advise waiting at least 2 months after the last dose of panitumumab before starting or resuming breastfeeding.

Fertility

Based on animal studies, panitumumab may impair fertility in females. The long-term effects on human fertility are not fully known, and patients should discuss these concerns with their medical team.

Question 10

What forms and strengths does Panitumumab come in?

Accepted Answer

Available Forms

Panitumumab is supplied as a sterile, colorless, preservative-free liquid solution. It is intended for intravenous administration and must be prepared and given by a healthcare provider in a clinical setting.

Intravenous Infusion: The medication is provided in single-dose vials. The solution is diluted into an infusion bag before being delivered directly into a vein.

Question 11

What is the FDA approval status of Panitumumab?

Accepted Answer

FDA Approval Status

Panitumumab received its initial FDA approval in 2006. It is indicated for the treatment of patients with wild-type RAS (KRAS and NRAS) metastatic colorectal cancer. It may be used as a first-line treatment in combination with chemotherapy or as a single agent if previous treatments have failed.

Recent Regulatory Updates

In 2024, the FDA approved panitumumab for use in combination with sotorasib. This specific indication is for adult patients with KRAS G12C-mutated colorectal cancer that has progressed after receiving other types of chemotherapy.

Boxed Warning

The medication carries a Boxed Warning for dermatologic toxicity . Most patients experience skin-related side effects, which can be severe. These reactions may include rash, skin peeling, and infections. Healthcare providers are advised to monitor patients closely and may need to adjust or stop treatment if severe reactions occur.

Testing Requirements

Because panitumumab is only effective in tumors with specific genetic characteristics, the FDA requires the use of an approved diagnostic test to confirm a patient's RAS mutation status before treatment begins. The drug is not recommended for patients whose tumors have RAS mutations.

Question 12

What should I know about Panitumumab and fda?

Accepted Answer

FDA Approval and Indications

Panitumumab was first approved by the U.S. Food and Drug Administration (FDA) in 2006. It is indicated for the treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC). This includes patients whose tumors do not have mutations in the KRAS or NRAS genes.

The FDA has approved panitumumab for use in several clinical scenarios:

As a first-line treatment combined with FOLFOX chemotherapy.

As a single agent for patients whose cancer has progressed after receiving chemotherapy regimens containing fluoropyrimidine, oxaliplatin, and irinotecan.

In combination with sotorasib for adult patients with KRAS G12C-mutated colorectal cancer who have already tried at least one other systemic therapy.

Regulatory Requirements and Warnings

The FDA requires the use of an FDA-approved test to confirm the absence of RAS mutations before starting panitumumab therapy. Clinical trials have shown that patients with RAS mutations do not benefit from this medication and may experience worse outcomes if it is used.

The FDA-approved labeling includes a Boxed Warning for dermatologic toxicity. This warning highlights the risk of severe skin reactions, such as dermatitis and cellulitis, which may lead to infectious complications. The FDA also monitors the drug for risks related to infusion reactions and lung disease.

Panitumumab

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?